Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | FDPS | P14324 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677429 | 1.00 | CA1 (0.55) | CA1ACE2ZDHHC7FAAHFFAR1 | |
| SCHEMBL14169844 | 1.00 | CA1 (0.55) | CA1ACE2ZDHHC7FAAHFFAR1 | |
| SCHEMBL6117662 | 1.00 | CA1 (0.55) | CA1ACE2ZDHHC7FAAHFFAR1 | |
| SCHEMBL8073537 | 1.00 | CA1 (0.55) | CA1ACE2ZDHHC7FAAHFFAR1 | |
| SCHEMBL22748707 | 1.00 | CA1 (0.55) | CA1ACE2ZDHHC7FAAHFFAR1 | |
| SCHEMBL8963949 | 1.00 | CA1 (0.55) | CA1ACE2ZDHHC7FAAHFFAR1 | |
| SCHEMBL11869095 | 1.00 | CA1 (0.55) | CA1ACE2ZDHHC7FAAHFFAR1 | |
| Hydrochloric Acid SCHEMBL28426136 | 0.98 | CA1 (0.53) | CA1ACE2ZDHHC7FAAHFFAR1 | |
| SCHEMBL5138404 | 0.98 | CA1 (0.57) | CA1ACE2ZDHHC7FAAHFFAR1 | |
| SCHEMBL16298859 | 0.98 | CA1 (0.57) | CA1ACE2ZDHHC7FAAHFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112154145-B | Piperazine azaspiro derivatives | 辉瑞大药厂 | 2023-10-17 | — | — | CN | claimed |
| CN-109996792-B | Heterocyclic compounds having activity as modulators of muscarinic M1 and/or M4 receptors in the treatment of CNS diseases and pain | 赫普泰雅治疗有限公司 | 2023-02-17 | — | — | CN | claimed |
| CN-106659719-A | Muscarinic receptor agonists | 赫普泰雅治疗有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-115403584-B | 2-thio-2, 3-dihydropyrimidine-4-one derivatives, pharmaceutical compositions, preparation methods and applications thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-114057740-B | Spiropyrimidinone derivatives, method for the production thereof, pharmaceutical compositions and use thereof | 上海赛默罗生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-112638477-B | Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117417355-A | Fused heterocyclic compound, preparation method and application thereof | 上海翊石医药科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117384155-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117242079-A | KRAS G12D inhibitors and uses thereof | 苏州赞荣医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-112154145-B | Piperazine azaspiro derivatives | 辉瑞大药厂 | 2023-10-17 | — | — | CN | disclosed |
| CN-111587112-B | Rho-related inhibitors of coiled-coil-containing protein kinases | 卡德门企业有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-100335509-C | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS INC (JP) | 2007-09-05 | — | — | CN | disclosed |
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | PFIZER, INC. | 2007-01-25 | — | — | US | disclosed |
| CN-1737016-A | Polar group-containing olefin copolymer, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS INC (JP) | 2006-02-22 | — | — | CN | disclosed |
| CN-1737017-A | Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof | MITSUI CHEMICALS INC (JP) | 2006-02-22 | — | — | CN | disclosed |
| CN-1219800-C | Polar group-containing olefin copolymer, thermoplastic resin composition containing the same, and use thereof | MITSUI CHEMICALS INC (JP) | 2005-09-21 | — | — | CN | disclosed |
| CN-1342715-A | Polar group-containing olefin copolymer, process for producing the same, thermoplastic resin composition containing the same, and use thereof | MITSUI CHEMICALS INC (JP) | 2002-04-03 | — | — | CN | disclosed |
| US-5463095-A | Process for the production of esters | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1995-10-31 | — | — | US | disclosed |
| EP-0629603-A1 | Process for the production of esters | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1994-12-21 | — | — | EP | disclosed |
| US-3968133-A | Carboxylation process for preparing linear fatty acids or esters | TEXACO INC. (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | GRIN1, GRIN3A, GRIN2C | CA1 1276/4885ACE2 2027/4885ZDHHC7 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.